Remove 2006 Remove Marketing Remove Pharmaceuticals
article thumbnail

2024 Gross-to-Net Realities at 9 Top Drugmakers: A New Era of Market Access

Drug Channels

It’s time for Drug Channels ’ annual update on drug pricing trends at the largest pharmaceutical manufacturers. As I noted in last week’s gross-to-net bubble analysis , manufacturers’ evolving market access strategies increasingly aim to offset—or circumvent—growing pricing pressure from both commercial and government payers.

article thumbnail

Strategic planning in ADC development: insights from Lonza

Drug Target Review

It was in 2006, when the bioconjugation field – particularly ADCs – was still in its infancy, that Bertholjotti entered this rapidly advancing space. He brings over 30 years of experience in the chemical and pharmaceutical industry, encompassing process development, manufacturing, program management, and commercial roles.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Forging a Path Forward for Substance Abuse Potential Studies With the Cross-Company Abuse Liability Council By Beatrice Setnik, PhD

Alta Sciences

The CCALC is a grassroots organization that was founded by several pharmaceutical industry members seeking clarity around the conduct of abuse and dependence potential assessments for novel drugs in development. This was in 2006, at a time when the FDA guidances on these topics had not yet been published.

article thumbnail

Analyzing biosimilar market dynamics in different patient populations

Drug Patent Watch

As we delve into the intricate world of biosimilar market dynamics, we’ll explore how these complex molecules are reshaping treatment paradigms across diverse patient populations. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 from 2020 to 2025[1].

article thumbnail

Gepirone

New Drug Approvals

2] Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals. [4] Jump up to: a b c d e “Gepirone – Fabre-Kramer Pharmaceuticals” AdisInsight. 1] It is taken orally. [1] 1] Gepirone acts as a partial agonist of the serotonin 5-HT 1A receptor. [1]

FDA 62
article thumbnail

Smaller Pharmacies, Bigger Impact: Inside Manufacturers’ Specialty Networks in 2025

Drug Channels

See The Top 15 Specialty Pharmacies of 2024: How PBMs, Health Systems, and Independents Are Shaping the Market. Pharmacies and Pharmacy Benefit Managers , we explore how pharmaceutical manufacturers structure their specialty pharmacy networksand how smaller, independent pharmacies have emerged as dominant players in exclusive networks.

article thumbnail

Master the Hidden Economics of Pharmaceuticals—In Under an Hour—with DCI's New eLearning Modules

Drug Channels

In todays fast-moving pharmaceutical marketplace, insight is everything. Why Professionals Choose DCI eLearning These modules were built from the ground up for pharmaceutical professionalsfrom seasoned experts to newcomers looking to understand the industry's complex web of relationships. pharmaceutical distribution.